Clinical research of neoadjuvant chemotherapy of endostar combined with TP for patients with advanced ovarian cancer
10.3760/cma.j.issn.1674-6090.2018.02.017
- VernacularTitle:重组人血管内皮抑制素联合多西他赛和顺铂方案新辅助化疗治疗晚期上皮性卵巢癌的临床疗效观察
- Author:
Suxia LI
1
;
Beibei LIN
;
Suxiu CHEN
Author Information
1. 325000温州,浙江省温州医科大学附属第一医院全科医学科
- Keywords:
Advanced ovarian cancer;
Endostatin;
Neoadjuvant chemotherapy;
Prognosis
- From:
Chinese Journal of Endocrine Surgery
2018;12(2):158-162
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical effect of neoadjuvant chemotherapy of endostar combined with docetaxel plus cisplatin(TP) on patients with advanced ovarian cancer.Methods 76 patients meeting the criterion were enrolled to the study,and they were randomly divided into study group and the control group.The control group were administered with TP,while the study group received endostar combined with TP.The clinical effects,conditions of surgery and long-term survival were observed.Results All patients finished 3 cycles of neoadjuvant chemotherapy.The incidence of adverse reactions (leucopenia,anorexia and fever) in the study group was higher than that in the control group,and the difference had statistical significance (P＜0.05).The level of CA125,tumor load and ascites volume decreased after chemotherapy (P＜0.05).The two groups had no significance difference in intraoperative ascites,blood loss,time of surgery or hospital stay (P＞0.05).The rate of residual lesion≤2 cm was 84.2％ in the study group,higher than that of the control group (60.5％),and the difference had statistical significance (P＜0.05).The overall 1-year and 3-year survival were 84.2％,and 63.1％ for the control group,86.8％ and 60.5％ for the study group,and the difference had no statistical significance (γ2=0.207,P=0.649).One-year and 3-year disease free survival were 89.4％ and 68.4％ for the control group,94.7％ and 76.3％ for the study group (γ2=4.042,P=0.040).Conclusion Endostar combined with TP (docetaxel plus cisplatin) for patients with advanced ovarian cancer is safe and effective,which can improve the success rate of cytoreductive surgery and local control rate of tumor.
